Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Hiroto Inaba, David T. Teachey, Colleen Annesley, Sandeep Batra, Jill C. Beck, Susan I. Colace, Stacy Cooper, Mari Dallas, Satiro De Oliveira, Kara M. Kelly, Carrie L. Kitko, Mira A. Kohorst, Matthew A. Kutny, Norman J. Lacayo, Cathy Lee‐Miller, Kathleen Ludwig, Lisa Madden, Kelly W. Maloney, David Spencer Mangum, Stephanie Massaro, David McCall, Perry Morocco, Brad Muller, Lindsey Murphy, Valentina Nardi, Jenna Rossoff, Laura G. Schuettpelz, Bijal Shah, Jessica Sun, Victor Wong, Gregory A. Yanik, Ajibola Awotiwon, Katie Stehman
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.